ERSP warns Beveragette not to overstate efficacy claims
This article was originally published in The Tan Sheet
Executive Summary
Beveragette Ventures can keep marketing claims that its GEM Keep It Cool Menopause Relief Drink reduces symptoms of menopause, but should drop modifiers like "dramatically" and "significantly," the Electronic Retailing Self-Regulation Program says in a report released Feb. 11. The industry watchdog explained the modifiers and testimonials suggesting consumers would receive "immediate results" overstated "the breadth of evidence" the firm submitted. However, the firm provided sufficient data to support claims that its supplement, made mostly of natural extract from black cohosh root, could help alleviate menopause-related hot flashes, night sweats and irritability. Beveragette said it would comply with the recommendations
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.